The growth in the historic period can be attributed to improved diagnosis of retinal disorders, expansion of ophthalmology specialty clinics, clinical success of anti-vegf therapies, increased aging population, wider availability of intravitreal injection procedures.
The growth in the forecast period can be attributed to growing prevalence of diabetic eye diseases, rising demand for durable treatment outcomes, expansion of personalized ophthalmic care, increased investments in retinal drug development, advancements in biologic drug delivery systems. Major trends in the forecast period include increasing adoption of long-acting retinal therapies, growing demand for reduced injection frequency treatments, expansion of dual-target ophthalmic drugs, rising focus on vision preservation solutions, enhanced use of advanced biologic formulations.
The increasing prevalence of ophthalmic conditions is expected to drive the growth of the vabysmo market in the coming years. Ophthalmic conditions are health issues related to the eyes that can impact vision or eye function, ranging from common problems like dry eyes to serious diseases such as cataracts, glaucoma, and macular degeneration. The rising prevalence of ophthalmic conditions is linked to various factors, including an aging population, higher diabetes rates, lifestyle influences, improved detection methods, and longer lifespans. Vabysmo supports ophthalmic patients by targeting and inhibiting key proteins responsible for the formation of abnormal blood vessels and fluid leakage in the eye, thereby enhancing vision and reducing the risk of further damage in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME), making it an essential therapy for preserving sight in affected individuals. For example, in August 2024, according to the Welsh Government, a UK-based government agency, ophthalmology departments in Wales reported over 35,000 admissions in 2023-24, representing a 5.8% increase from the previous year. Therefore, the increasing prevalence of ophthalmic conditions is fueling the growth of the vabysmo market.
The increasing aging population is expected to drive the growth of the Vabysmo market in the coming years. An aging population is defined by a rising share of elderly individuals due to longer life expectancy and lower birth rates. The growing aging population results from factors such as improved healthcare leading to longer life expectancy and reduced birth rates, which together increase the proportion of older individuals. Vabysmo supports the aging population by treating retinal diseases, enhancing vision, and helping prevent vision loss, which is prevalent among older adults. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the expanding aging population is fueling the growth of the Vabysmo market.
The key trend in the Vabysmo market is centered on obtaining regulatory approvals to broaden its reach and enter new markets, driving adoption among healthcare providers and ensuring wider patient access to its innovative treatment for retinal diseases. Regulatory approvals are official authorizations issued by government agencies to confirm that a product, such as a drug or medical device, meets safety, efficacy, and quality standards, providing benefits such as market access, consumer confidence, and legal compliance. For instance, in December 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received approval from the European Medicines Agency for its Vabysmo prefilled syringe for the treatment of three retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO), which together affect over nine million people across Europe. As the first prefilled syringe with a bispecific antibody, Vabysmo PFS offers a convenient, ready-to-use option paired with a CE-marked needle designed for intravitreal injections. By targeting Angiopoietin-2 (Ang-2) and VEGF-A pathways, the treatment stabilizes blood vessels, reduces inflammation, and delivers substantial improvements in vision. This innovation simplifies administration for retina specialists and reduces treatment burdens.
Major companies operating in the vabysmo market are F. Hoffmann-La Roche AG.
North America was the largest region in the vabysmo market in 2025. The regions covered in the vabysmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vabysmo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the vabysmo market by increasing costs of imported biologic raw materials, sterile syringes, formulation reagents, and cold-chain logistics solutions. North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces higher costs for branded ophthalmic imports. These tariffs contribute to higher treatment costs and reimbursement pressures. However, they are also encouraging regional biologics manufacturing and localized ophthalmic drug packaging capabilities.
The vabysmo market research report is one of a series of new reports that provides vabysmo market statistics, including vabysmo industry global market size, regional shares, competitors with a vabysmo market share, detailed vabysmo market segments, market trends and opportunities, and any further data you may need to thrive in the vabysmo industry. This vabysmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vabysmo is a prescription drug used to manage retinal conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). It blocks VEGF and Ang-2, helping to decrease retinal fluid buildup and protect against vision loss. Vabysmo is given as an injection directly into the eye, providing a long-lasting treatment option with fewer injections needed compared to conventional therapies.
The primary indications for Vabysmo include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), uveitis, and retinal vein occlusion. Wet age-related macular degeneration is characterized by the growth of abnormal blood vessels under the retina, resulting in vision loss in older adults. The available formulations include injectable solutions and pre-filled syringes. These are supplied through multiple distribution channels such as hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies, and are used by various end users including adults and geriatric patients.
The vabysmo market consists of sales of prefilled syringes, preservative-free formulation, vials for reconstitution, and injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to growing prevalence of diabetic eye diseases, rising demand for durable treatment outcomes, expansion of personalized ophthalmic care, increased investments in retinal drug development, advancements in biologic drug delivery systems. Major trends in the forecast period include increasing adoption of long-acting retinal therapies, growing demand for reduced injection frequency treatments, expansion of dual-target ophthalmic drugs, rising focus on vision preservation solutions, enhanced use of advanced biologic formulations.
The increasing prevalence of ophthalmic conditions is expected to drive the growth of the vabysmo market in the coming years. Ophthalmic conditions are health issues related to the eyes that can impact vision or eye function, ranging from common problems like dry eyes to serious diseases such as cataracts, glaucoma, and macular degeneration. The rising prevalence of ophthalmic conditions is linked to various factors, including an aging population, higher diabetes rates, lifestyle influences, improved detection methods, and longer lifespans. Vabysmo supports ophthalmic patients by targeting and inhibiting key proteins responsible for the formation of abnormal blood vessels and fluid leakage in the eye, thereby enhancing vision and reducing the risk of further damage in conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME), making it an essential therapy for preserving sight in affected individuals. For example, in August 2024, according to the Welsh Government, a UK-based government agency, ophthalmology departments in Wales reported over 35,000 admissions in 2023-24, representing a 5.8% increase from the previous year. Therefore, the increasing prevalence of ophthalmic conditions is fueling the growth of the vabysmo market.
The increasing aging population is expected to drive the growth of the Vabysmo market in the coming years. An aging population is defined by a rising share of elderly individuals due to longer life expectancy and lower birth rates. The growing aging population results from factors such as improved healthcare leading to longer life expectancy and reduced birth rates, which together increase the proportion of older individuals. Vabysmo supports the aging population by treating retinal diseases, enhancing vision, and helping prevent vision loss, which is prevalent among older adults. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the expanding aging population is fueling the growth of the Vabysmo market.
The key trend in the Vabysmo market is centered on obtaining regulatory approvals to broaden its reach and enter new markets, driving adoption among healthcare providers and ensuring wider patient access to its innovative treatment for retinal diseases. Regulatory approvals are official authorizations issued by government agencies to confirm that a product, such as a drug or medical device, meets safety, efficacy, and quality standards, providing benefits such as market access, consumer confidence, and legal compliance. For instance, in December 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, received approval from the European Medicines Agency for its Vabysmo prefilled syringe for the treatment of three retinal conditions: neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion (RVO), which together affect over nine million people across Europe. As the first prefilled syringe with a bispecific antibody, Vabysmo PFS offers a convenient, ready-to-use option paired with a CE-marked needle designed for intravitreal injections. By targeting Angiopoietin-2 (Ang-2) and VEGF-A pathways, the treatment stabilizes blood vessels, reduces inflammation, and delivers substantial improvements in vision. This innovation simplifies administration for retina specialists and reduces treatment burdens.
Major companies operating in the vabysmo market are F. Hoffmann-La Roche AG.
North America was the largest region in the vabysmo market in 2025. The regions covered in the vabysmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vabysmo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are influencing the vabysmo market by increasing costs of imported biologic raw materials, sterile syringes, formulation reagents, and cold-chain logistics solutions. North America and Europe are most affected due to dependence on global biologics supply chains, while Asia-Pacific faces higher costs for branded ophthalmic imports. These tariffs contribute to higher treatment costs and reimbursement pressures. However, they are also encouraging regional biologics manufacturing and localized ophthalmic drug packaging capabilities.
The vabysmo market research report is one of a series of new reports that provides vabysmo market statistics, including vabysmo industry global market size, regional shares, competitors with a vabysmo market share, detailed vabysmo market segments, market trends and opportunities, and any further data you may need to thrive in the vabysmo industry. This vabysmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Vabysmo is a prescription drug used to manage retinal conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). It blocks VEGF and Ang-2, helping to decrease retinal fluid buildup and protect against vision loss. Vabysmo is given as an injection directly into the eye, providing a long-lasting treatment option with fewer injections needed compared to conventional therapies.
The primary indications for Vabysmo include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR), uveitis, and retinal vein occlusion. Wet age-related macular degeneration is characterized by the growth of abnormal blood vessels under the retina, resulting in vision loss in older adults. The available formulations include injectable solutions and pre-filled syringes. These are supplied through multiple distribution channels such as hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies, and are used by various end users including adults and geriatric patients.
The vabysmo market consists of sales of prefilled syringes, preservative-free formulation, vials for reconstitution, and injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Vabysmo Market Characteristics
3. Vabysmo Market Supply Chain Analysis
4. Global Vabysmo Market Trends and Strategies
5. Vabysmo Market Analysis of End Use Industries
7. Global Vabysmo Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Vabysmo Total Addressable Market (TAM) Analysis for the Market
9. Vabysmo Market Segmentation
10. Vabysmo Market Regional and Country Analysis
11. Asia-Pacific Vabysmo Market
12. China Vabysmo Market
13. India Vabysmo Market
14. Japan Vabysmo Market
15. Australia Vabysmo Market
16. South Korea Vabysmo Market
17. Western Europe Vabysmo Market
18. UK Vabysmo Market
19. Germany Vabysmo Market
20. France Vabysmo Market
21. Eastern Europe Vabysmo Market
22. North America Vabysmo Market
23. USA Vabysmo Market
24. Canada Vabysmo Market
25. South America Vabysmo Market
26. Middle East Vabysmo Market
27. Africa Vabysmo Market
29. Vabysmo Market Competitive Landscape and Company Profiles
32. Vabysmo Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Vabysmo Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses vabysmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vabysmo? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vabysmo market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Wet Age-Related Macular Degeneration (wAMD); Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Uveitis; Retinal Vein Occlusion2) By Formulation: Injectable Solutions; Pre-filled Syringes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies; Online Pharmacies
4) By End User: Adult; Geriatric
Companies Mentioned: F. Hoffmann-La Roche AG
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Vabysmo market report include:- F. Hoffmann-La Roche AG
